Immutep Limited Revenue Growth Rates (IMMP), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Immutep Limited  (NASDAQ: IMMP)
 

IMMP's Revenue Growth by Quarter and Year

Immutep Limited's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IMMP Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 10.33
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 10.33

IMMPs Annual Revenue
Immutep Limited's Revenue in the fiscal year 2025 $ 10.33 millions
Immutep Limited's Revenue in the fiscal year 2024 $ 7.84 millions
Immutep Limited's Revenue in the fiscal year 2023 $ 5.20 millions
Immutep Limited's Revenue in the fiscal year 2022 $ 6.76 millions
Immutep Limited's Revenue in the fiscal year 2021 $ 3.97 millions




IMMP Revenue fourth quarter 2025 Y/Y Growth Comment
Immutep Limited achieved in the fourth quarter 2025, above Company average Revenue growth of 31.78% year on year, to $ 10.33 millions.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Revenue growth. While Immutep Limited' s Revenue rise of 31.78% ranks overall at the positon no. 3062 in the fourth quarter 2025.


IMMP Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 31.78 % 50.77 % -23.08 % 70.28 %
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   31.78 % 50.77 % -23.08 % -

Financial Statements
Immutep Limited's fourth quarter 2025 Revenue $ 10.33 millions IMMP's Income Statement
Immutep Limited's fourth quarter 2024 Revenue $ 7.84 millions Quarterly IMMP's Income Statement


IMMP Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   31.78 % 50.77 % -23.08 % -


Back to IMMP Growth rate Comparisons >> Back to IMMP Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #402
Overall #3062

Revenue Y/Y Growth Statistics
High Average Low
70.31 % 10.57 % -47.02 %
(Jun 30 2022)   (Jun 30 2021)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #402
Overall #3062
Revenue Y/Y Growth Statistics
High Average Low
70.31 % 10.57 % -47.02 %
(Jun 30 2022)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Immutep Limited's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMMP's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


IMMP's IV. Quarter Q/Q Revenue Comment


Immutep Limited's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Jun 30 2021)
Cumulative Revenue 12 Months Ending $ 10.33 $ 7.84 $ 5.20 $ 6.76 $ 3.97
Y / Y Revenue Growth (TTM) 31.8 % 50.74 % -23.05 % 70.31 % -64.16 %
Year on Year Revenue Growth Overall Ranking # 3062 # 3145 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 31.8 % 50.74 % -23.05 % 70.31 % -64.16 %
Seq. Revenue Growth (TTM) Overall Ranking # 3062 # 3228 # 0 # 0 # 0


Cumulative Revenue growth Comment
Assuming the Immutep Limited's fiscal year would have ended in Jun 30 2025, Immutep Limited would have reprted above average annual Revenue rise of 31.8% year on year, of $ 10 millions.
This marks a slow-down of the companys growth trends and from the 50.74% increase in Jun 30 2024.

In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3062, from total ranking in previous quarter at 3145.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 402
Overall # 3062

Revenue TTM Y/Y Growth Statistics
High Average Low
70.31 %
 10.57 %
-47.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 402
S&P 500 # 3062
Cumulative Revenue growth Comment
Assuming the Immutep Limited's fiscal year would have ended in Jun 30 2025, Immutep Limited would have reprted above average annual Revenue rise of 31.8% year on year, of $ 10 millions.
This marks a slow-down of the companys growth trends and from the 50.74% increase in Jun 30 2024.

In the Healthcare sector 401 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3062, from total ranking in previous quarter at 3145.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 402
Overall # 3062

Revenue TTM Y/Y Growth Statistics
High Average Low
70.31 %
10.57 %
-47.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 402
S&P 500 # 3062




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IMMP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2025
Ideaya Biosciences Inc 55.37%$ 55.371 millions
Urogen Pharma Ltd 54.03%$ 54.028 millions
The Pennant Group Inc 53.17%$ 53.168 millions
Halozyme Therapeutics Inc 51.60%$ 51.596 millions
Nephros Inc 51.08%$ 51.084 millions
Adaptive Biotechnologies Corporation51.04%$ 51.038 millions
Mirum Pharmaceuticals Inc 49.81%$ 49.810 millions
Ascendis Pharma A49.14%$ 49.137 millions
Hyperfine Inc 48.82%$ 48.824 millions
Intelligent Bio Solutions Inc 47.62%$ 47.619 millions
Gossamer Bio Inc 47.13%$ 47.127 millions
Electrocore Inc 46.11%$ 46.111 millions
Mannkind Corporation45.82%$ 45.820 millions
Hologic Inc44.84%$ 44.836 millions
Ensysce Biosciences Inc 44.39%$ 44.389 millions
Profound Medical Corp 43.13%$ 43.127 millions
Regenxbio Inc 43.00%$ 43.005 millions
Xeris Biopharma Holdings Inc 42.78%$ 42.776 millions
Eli Lilly And Company42.56%$ 42.557 millions
Edwards Lifesciences Corporation42.48%$ 42.484 millions
Rani Therapeutics Holdings Inc 42.12%$ 42.121 millions
Establishment Labs Holdings Inc 41.85%$ 41.854 millions
The Oncology Institute Inc 41.58%$ 41.579 millions
Cytosorbents Corporation41.55%$ 41.553 millions
Vystar Corporation41.19%$ 41.186 millions
Prelude Therapeutics Inc41.00%$ 41.000 millions
Biodesix Inc 40.76%$ 40.756 millions
Ligand Pharmaceuticals Incorporated40.01%$ 40.008 millions
Femasys Inc 39.84%$ 39.844 millions
Natera Inc 39.79%$ 39.793 millions


About Immutep Limited Revenue Growth Rates (IMMP), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Immutep Ltd (CIK 1506184).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-25-249346
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Immutep Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.